-
1
-
-
77649173208
-
Lapatinib restores hormone sensitivity with differential effects on ER signaling in cell models of HER2-negative breast cancer with acquired endocrine resistance
-
Leary AF, Drury S, Detre S, et al. Lapatinib restores hormone sensitivity with differential effects on ER signaling in cell models of HER2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 2010;16:1486-97.
-
(2010)
Clin Cancer Res
, Issue.16
, pp. 1486-1497
-
-
Leary, A.F.1
Drury, S.2
Detre, S.3
-
2
-
-
42049121934
-
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance
-
Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008;29:217-33.
-
(2008)
Endocr Rev
, vol.29
, pp. 217-233
-
-
Arpino, G.1
Wiechmann, L.2
Osborne, C.K.3
Schiff, R.4
-
3
-
-
0034899503
-
Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells
-
Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 2001;15:1344-59.
-
(2001)
Mol Endocrinol
, vol.15
, pp. 1344-1359
-
-
Oh, A.S.1
Lorant, L.A.2
Holloway, J.N.3
Miller, D.L.4
Kern, F.G.5
El-Ashry, D.6
-
4
-
-
33645730357
-
Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors
-
Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 2006;66:3903-11.
-
(2006)
Cancer Res
, vol.66
, pp. 3903-3911
-
-
Creighton, C.J.1
Hilger, A.M.2
Murthy, S.3
Rae, J.M.4
Chinnaiyan, A.M.5
El-Ashry, D.6
-
5
-
-
0035476866
-
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer
-
Rusnak DW, Affleck K, Cockerill SG, et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001;61:7196-203.
-
(2001)
Cancer Res
, vol.61
, pp. 7196-7203
-
-
Rusnak, D.W.1
Affleck, K.2
Cockerill, S.G.3
-
6
-
-
33750468717
-
Reverting estrogen-receptor- negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
-
Munzone E, Curigliano G, Rocca A, et al. Reverting estrogen-receptor- negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res 2006;8:R4.
-
(2006)
Breast Cancer Res
, vol.8
-
-
Munzone, E.1
Curigliano, G.2
Rocca, A.3
-
7
-
-
33646746413
-
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer
-
Xia W, Bacus S, Hegde P, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 2006; 103:7795-800.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 7795-7800
-
-
Xia, W.1
Bacus, S.2
Hegde, P.3
-
8
-
-
73949105921
-
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study
-
Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-37.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5529-5537
-
-
Kaufman, B.1
Mackey, J.R.2
Clemens, M.R.3
-
9
-
-
41949104971
-
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial
-
Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008;26:1059-65.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1059-1065
-
-
Dowsett, M.1
Allred, C.2
Knox, J.3
-
10
-
-
35348877882
-
Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy
-
Bartlett JM, Ellis IO, Dowsett M, et al. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol 2007;25:4423-30.
-
(2007)
J Clin Oncol
, vol.25
, pp. 4423-4430
-
-
Bartlett, J.M.1
Ellis, I.O.2
Dowsett, M.3
-
11
-
-
73149115341
-
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
-
Johnston S, Pippen J, Jr., Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5538-5546
-
-
Johnston, S.1
Pippen Jr., J.2
Pivot, X.3
-
12
-
-
69849105168
-
Progression-free survival (PFS) of patients with HER2-negative, estrogen receptor (ER)-low metastasic breast cancer (MBC) with the addition of lapatinib to letrozole: Biomarker results of EGF30008
-
45s
-
Finn RS, Press M, Dering J, et al. Progression-free survival (PFS) of patients with HER2-negative, estrogen receptor (ER)-low metastasic breast cancer (MBC) with the addition of lapatinib to letrozole: Biomarker results of EGF30008. Proc Am Soc Clin Oncol 2009;27:45s.
-
(2009)
Proc Am Soc Clin Oncol
, vol.27
-
-
Finn, R.S.1
Press, M.2
Dering, J.3
|